000151338 001__ 151338
000151338 005__ 20251017144625.0
000151338 0247_ $$2doi$$a10.3390/biomedicines9101429
000151338 0248_ $$2sideral$$a126534
000151338 037__ $$aART-2021-126534
000151338 041__ $$aeng
000151338 100__ $$aRey-Reñones, C.
000151338 245__ $$aType 2 diabetes mellitus and cancer: Epidemiology, physiopathology and prevention
000151338 260__ $$c2021
000151338 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151338 5203_ $$aIndividuals with type 2 diabetes mellitus are at greater risk of developing cancer and of dying from it. Both diseases are age-related, contributing to the impact of population aging on the long-term sustainability of health care systems in European Union countries. The purpose of this narrative review was to describe, from epidemiological, pathophysiological and preventive perspectives, the links between type 2 diabetes mellitus and the most prevalent cancers in these patients. Multiple metabolic abnormalities that may occur in type 2 diabetes mellitus, particularly obesity, could explain the increased cancer risk. In addition, the effectiveness of drugs commonly used to treat type 2 diabetes mellitus (e.g., metformin and thiazolidinediones) has been broadly evaluated in cancer prevention. Thus, a better understanding of the links between type 2 diabetes mellitus and cancer will help to identify the contributing factors and the pathophysiological pathways and to design personalized preventive strategies. The final goal is to facilitate healthy aging and the prevention of cancer and other diseases related with type 2 diabetes mellitus, which are among the main sources of disability and death in the European Union and worldwide.
000151338 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000151338 590__ $$a4.757$$b2021
000151338 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b121 / 297 = 0.407$$c2021$$dQ2$$eT2
000151338 591__ $$aPHARMACOLOGY & PHARMACY$$b87 / 279 = 0.312$$c2021$$dQ2$$eT1
000151338 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b62 / 139 = 0.446$$c2021$$dQ2$$eT2
000151338 592__ $$a0.874$$b2021
000151338 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000151338 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ1
000151338 594__ $$a3.0$$b2021
000151338 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151338 700__ $$aBaena-Díez, J.M.
000151338 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, I.$$uUniversidad de Zaragoza
000151338 700__ $$aMiquel, C.
000151338 700__ $$aGrau, M.
000151338 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000151338 773__ $$g9, 10 (2021), 1429 [16 pp.]$$tBiomedicines$$x2227-9059
000151338 8564_ $$s694157$$uhttps://zaguan.unizar.es/record/151338/files/texto_completo.pdf$$yVersión publicada
000151338 8564_ $$s2667826$$uhttps://zaguan.unizar.es/record/151338/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151338 909CO $$ooai:zaguan.unizar.es:151338$$particulos$$pdriver
000151338 951__ $$a2025-10-17-14:23:24
000151338 980__ $$aARTICLE